The development of new efficient therapeutics for the
treatment of tuberculosis (TB) is an important endeavor
because TB remains a leading source of mortality by
infectious disease and kills more than 1 million people
annually [1]. Mycobacterium tuberculosis (MTB) is the
main cause of TB, and the evolution of MTB new
virulent forms especially multidrug-resistant MTB
(MDR-MTB) is becoming a major and alarming threat in
most regions worldwide [2,3].